Less Ads, More Data, More Tools Register for FREE

Pin to quick picksODX.L Regulatory News (ODX)

  • There is currently no data for ODX

Statement re. Media Comment

15 Jun 2021 10:49

RNS Number : 9486B
Omega Diagnostics Group PLC
15 June 2021
 

OMEGA DIAGNOSTICS GROUP PLC

("Omega" or the "Company" or the "Group")

 

Statement re. Media Comment

 

Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the recent media comment that Mologic Ltd have requested for Porton Down to evaluate their lateral flow antigen test with an independent party observing.

 

This process has no implications on the UK Government manufacturing contract that Omega has in place with the Department of Health and Social Care ("DHSC"). Under that contract Omega will provide manufacturing capacity for COVID-19 lateral flow antigen tests utilising the key pieces of manufacturing equipment loaned by the UK Government for that purpose and Omega will manufacture whichever test is approved for use by the DHSC. As clarified on 7 June 2021 the ability to supply tests that are produced within the UK remains a key priority for the DHSC and to that end the DHSC have facilitated initial commercial discussions between Omega and a number of companies with lateral flow antigen tests to potentially provide UK manufacturing services.

 

As already announced on 8 June 2021 Omega is in the process of seeking CE marking of its VISITECT® COVID-19 Antigen test, as a self-test. Final preparations for a submission to the U.S. Food and Drug Administration (FDA) requesting Emergency Use Authorization (EUA) for this test is also underway.

 

Recently published study data confirms that Mologic's lateral flow antigen test, being commercialised by Omega as the VISITECT® COVID-19 Antigen test, demonstrates high diagnostic accuracy (specificity and sensitivity) fulfilling WHO target accuracy with a high sensitivity (93.2%-98.4%) detecting individuals with high viral load infections (Ct

 

Further details of the study and the FIND report can be seen using the links below:

https://www.londonstockexchange.com/news-article/ODX/positive-data-for-covid-19-antigen-test/14998113

https://www.londonstockexchange.com/news-article/ODX/positive-data-for-mologic-covid-19-antigen-test/14963499

 

 Contacts: 

 

Omega Diagnostics Group PLC

www.omegadiagnostics.com

Colin King, Chief Executive

via Walbrook PR

Kieron Harbinson, Group Finance Director

 

 

 

finnCap Ltd

Tel: 020 7220 0500

Geoff Nash/Edward Whiley (Corporate Finance)

 

Alice Lane (ECM)

 

 

 

Walbrook PR Limited

Tel: 020 7933 8780 or omega@walbrookpr.com

Paul McManus

Mob: 07980 541 893

Lianne Cawthorne

Mob: 07584 391 303

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
SPCEANKSFLKFEEA
Date   Source Headline
16th Jul 20127:00 amRNSDirector/PDMR Shareholding
9th Jul 20124:35 pmRNSDirector/PDMR Shareholding
6th Jul 201210:37 amRNSDirector Dealing
6th Jul 20127:00 amRNSGrant of Options
2nd Jul 20127:00 amRNSFinal Results
19th Jun 20127:00 amRNSCollaboration with the Burnet Institute, Melbourne
16th Apr 20127:00 amRNSTrading Statement
2nd Apr 201210:51 amRNSDirector Shareholding
28th Mar 20123:08 pmRNSDirectorate Change
30th Jan 201211:57 amRNSDirector/PDMR Shareholding
17th Jan 20129:00 amRNSDirectorate Change
25th Nov 20117:00 amRNSInterim Results
7th Nov 20117:00 amRNSChange of Adviser
10th Oct 20117:00 amRNSTrading Update & Notice of Results
23rd Aug 201111:29 amRNSResult of AGM
15th Aug 20112:05 pmRNSDirector/PDMR Shareholding
4th Jul 20117:00 amRNSFinal Results
30th Jun 20111:18 pmRNSDirectorate Change
27th May 201111:58 amRNSHolding(s) in Company
24th May 20117:00 amRNSTen year exclusive distribution agreement
12th Apr 20117:00 amRNSTrading Update & Management Appointments
28th Mar 20117:35 amRNSExclusive Licence Agreement
23rd Feb 20119:20 amRNSHolding(s) in Company
17th Jan 20117:00 amRNSHolding(s) in Company
23rd Dec 201010:53 amRNSHolding(s) in Company
23rd Dec 201010:53 amRNSHolding(s) in Company
21st Dec 20104:40 pmRNSHolding(s) in Company
21st Dec 20104:36 pmRNSTotal Voting Rights
20th Dec 20103:29 pmRNSHolding(s) in Company
17th Dec 20109:51 amRNSResult of General Meeting
26th Nov 20107:00 amRNSDistribution Agreement: Food DetectiveT in India
26th Nov 20107:00 amRNSHalf Yearly Report
17th Nov 20107:00 amRNSPlacing and Acquisition
13th Oct 20107:00 amRNSTrading Statement
19th Aug 20102:32 pmRNSAGM Statement
23rd Jul 201010:20 amRNSHolding(s) in Company
16th Jul 20107:00 amRNSFinal Results
26th May 20107:00 amRNSCo-Tek supply agreement
30th Apr 20102:26 pmRNSHolding(s) in Company
13th Apr 20107:00 amRNSTrading Statement
22nd Dec 20098:43 amRNSDirectorate Change
11th Dec 20097:00 amRNSTrading Statement
27th Nov 20097:00 amRNSHalf Yearly Report
4th Nov 200910:19 amRNSHolding(s) in Company
21st Oct 20094:51 pmRNSEnd of offer period
21st Oct 200910:50 amRNSRule 8.3- Omega Diagnostics Group Plc
20th Oct 200911:52 amRNSRule 8.3- Omega Diagnostics Group Plc
20th Oct 200911:43 amRNSRule 8.3- Omega Diagnostics
19th Oct 20097:00 amRNSStatement re Possible Offer
14th Oct 200911:12 amRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.